Glaukos (NYSE:GKOS) had its price target raised by BMO Capital Markets from $59.00 to $68.00 in a research report report published on Wednesday morning, The Fly reports. BMO Capital Markets currently has a market perform rating on the medical instruments supplier’s stock.

A number of other analysts have also issued reports on GKOS. Zacks Investment Research raised shares of Glaukos from a sell rating to a hold rating in a research report on Thursday, May 10th. JPMorgan Chase & Co. lowered shares of Glaukos from an overweight rating to a neutral rating in a research report on Thursday, June 21st. TheStreet raised shares of Glaukos from a d rating to a c- rating in a research report on Monday, June 25th. ValuEngine raised shares of Glaukos from a hold rating to a buy rating in a research report on Friday, July 6th. Finally, Stifel Nicolaus increased their price target on shares of Glaukos from $32.00 to $35.00 and gave the stock a hold rating in a research report on Friday, August 3rd. Four equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company. The company has an average rating of Buy and an average price target of $56.90.

Shares of GKOS opened at $61.51 on Wednesday. Glaukos has a one year low of $23.08 and a one year high of $70.91. The stock has a market capitalization of $2.20 billion, a price-to-earnings ratio of 1,261.80 and a beta of 1.46.

Glaukos (NYSE:GKOS) last announced its earnings results on Thursday, August 2nd. The medical instruments supplier reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.03). Glaukos had a negative return on equity of 4.11% and a negative net margin of 3.49%. The firm had revenue of $43.16 million during the quarter, compared to analyst estimates of $40.51 million. During the same quarter in the previous year, the business earned ($0.10) earnings per share. The business’s quarterly revenue was up 4.5% compared to the same quarter last year. sell-side analysts predict that Glaukos will post -0.55 EPS for the current year.

In related news, CEO Thomas William Burns sold 150,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 7th. The shares were sold at an average price of $38.78, for a total transaction of $5,817,000.00. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, COO Chris M. Calcaterra sold 7,759 shares of the firm’s stock in a transaction that occurred on Tuesday, June 19th. The shares were sold at an average price of $44.01, for a total transaction of $341,473.59. Following the transaction, the chief operating officer now directly owns 247,759 shares in the company, valued at approximately $10,903,873.59. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 708,273 shares of company stock worth $38,638,566. Insiders own 11.60% of the company’s stock.

A number of institutional investors and hedge funds have recently modified their holdings of the stock. BlackRock Inc. raised its position in Glaukos by 20.5% during the second quarter. BlackRock Inc. now owns 2,416,215 shares of the medical instruments supplier’s stock valued at $98,197,000 after acquiring an additional 411,836 shares in the last quarter. Baillie Gifford & Co. raised its position in shares of Glaukos by 8.2% in the second quarter. Baillie Gifford & Co. now owns 1,211,663 shares of the medical instruments supplier’s stock valued at $49,242,000 after purchasing an additional 92,050 shares during the period. Waddell & Reed Financial Inc. raised its position in shares of Glaukos by 68.4% in the second quarter. Waddell & Reed Financial Inc. now owns 1,115,815 shares of the medical instruments supplier’s stock valued at $45,346,000 after purchasing an additional 453,167 shares during the period. FMR LLC raised its position in shares of Glaukos by 19.3% in the second quarter. FMR LLC now owns 1,056,162 shares of the medical instruments supplier’s stock valued at $42,923,000 after purchasing an additional 171,092 shares during the period. Finally, Federated Investors Inc. PA raised its position in shares of Glaukos by 75.7% in the first quarter. Federated Investors Inc. PA now owns 790,750 shares of the medical instruments supplier’s stock valued at $24,379,000 after purchasing an additional 340,696 shares during the period.

About Glaukos

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development and commercialization of surgical devices and sustained pharmaceutical therapies designed to treat glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma.

Featured Article: Relative Strength Index

The Fly

Analyst Recommendations for Glaukos (NYSE:GKOS)

Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.